Literature DB >> 9301541

Complement-activating ability of leucocytes from patients with complement factor I deficiency.

H V Marquart1, J M Rasmussen, R G Leslie.   

Abstract

Previous studies from this laboratory have shown that normal peripheral blood B cells are capable of activating complement via the alternative pathway (AP), that the activation is associated with complement receptor type 2 (CR2) expression, and that erythrocytes at normal blood levels partially inhibit the activation. The purpose of the present study was to investigate whether factor I (FI) deficiency, which leads to continued formation of the AP convertase (C3bBb) resulting in the consumption of factor B and C3 and large scale generation of C3b fragments, affects the phenotype and/or function of the patients' B cells. Using flow cytometry, peripheral blood leucocytes (PBL) from two FI-deficient patients were investigated for expression of complement receptors and complement regulatory proteins, in vivo-deposited C3 fragments and in vitro complement-activating ability. CR1 levels on B cells were significantly lower in FI-deficient patients than in normal individuals, whereas CR2 levels were found to be reduced, although not to a significant extent. CR1 levels on monocytes and polymorphonuclear leucocytes (PMN) were found to be normal or slightly raised. All leucocyte subpopulations were found to be covered in vivo with C3b fragments. AP activation on B cells from FI-deficient patients in homologous serum was significantly reduced compared with that for normal individuals, whereas no in vitro activation was seen in autologous serum. In addition, the in vivo-bound C3b fragments were degraded to C3d,g when the patients' PBL were incubated in homologous serum containing EDTA. Finally, the patients, erythrocytes failed to exert any inhibition on AP activation in homologous serum.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9301541      PMCID: PMC1364021          DOI: 10.1046/j.1365-2567.1997.00273.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  29 in total

1.  The isolation and characterization of the V-H domain from rabbit heavy chains of different a locus allotype.

Authors:  L E Mole; M D Geier; M E Koshland
Journal:  J Immunol       Date:  1975-05       Impact factor: 5.422

2.  Markedly impaired humoral immune response in mice deficient in complement receptors 1 and 2.

Authors:  H Molina; V M Holers; B Li; Y Fung; S Mariathasan; J Goellner; J Strauss-Schoenberger; R W Karr; D D Chaplin
Journal:  Proc Natl Acad Sci U S A       Date:  1996-04-16       Impact factor: 11.205

3.  Immunoglobulin production by human peripheral lymphocytes induced by anti-C3 receptor antibodies.

Authors:  M R Daha; A C Bloem; R E Ballieux
Journal:  J Immunol       Date:  1984-03       Impact factor: 5.422

4.  Increased expression of C3b receptors on polymorphonuclear leukocytes induced by chemotactic factors and by purification procedures.

Authors:  D T Fearon; L A Collins
Journal:  J Immunol       Date:  1983-01       Impact factor: 5.422

5.  C3b inactivator deficiency with immune complex manifestations.

Authors:  P Solal-Celigny; M Laviolette; J Hebert; P C Atkins; M Sirois; G Brun; G Lehner-Netsch; J M Delâge
Journal:  Clin Exp Immunol       Date:  1982-01       Impact factor: 4.330

6.  Restoration by purified C3b inactivator of complement-mediated function in vivo in a patient with C3b inactivator deficiency.

Authors:  J B Ziegler; C A Alper; R S Rosen; P J Lachmann; L Sherington
Journal:  J Clin Invest       Date:  1975-03       Impact factor: 14.808

7.  Restoration of complement function in vivo by plasma infusion in factor I (C3b inactivator) deficiency.

Authors:  D J Barrett; M D Boyle
Journal:  J Pediatr       Date:  1984-01       Impact factor: 4.406

8.  Complement biosynthesis by the human hepatoma-derived cell line HepG2.

Authors:  K M Morris; D P Aden; B B Knowles; H R Colten
Journal:  J Clin Invest       Date:  1982-10       Impact factor: 14.808

9.  Studies in vivo and in vitro on an abnormality in the metabolism of C3 in a patient with increased susceptibility to infection.

Authors:  C A Alper; N Abramson; R B Johnston; J H Jandl; F S Rosen
Journal:  J Clin Invest       Date:  1970-11       Impact factor: 14.808

10.  A second case of human C3b inhibitor (KAF) deficiency.

Authors:  R A Thompson; P J Lachmann
Journal:  Clin Exp Immunol       Date:  1977-01       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.